Impact of short-term application of sodium-glucose transporter 2 inhibitor on acute kidney injury in patients with type 2 diabetes mellitus underwent percutaneous coronary intervention
10.3760/cma.j.cn441217-20241023-01036
- VernacularTitle:短期应用钠-葡萄糖共转运蛋白抑制剂对2型糖尿病患者经皮冠状动脉介入术后急性肾损伤发生率的影响
- Author:
Shicheng YANG
1
;
Xiufeng ZHAI
;
Yufeng MA
;
Peng ZHANG
;
Hongliang CONG
;
Naikuan FU
Author Information
1. 天津大学胸科医院心内科，天津 300222
- Publication Type:Journal Article
- Keywords:
Sodium-glucose transporter 2 inhibitors;
Contrast media;
Acute kidney injury;
Percutaneous coronary intervention
- From:
Chinese Journal of Nephrology
2025;41(11):876-879
- CountryChina
- Language:Chinese
-
Abstract:
It was a retrospective study. The propensity score matching was applied to divide the type 2 diabetes mellitus (T2DM) patients who have underwent percutaneous coronary intervention (PCI) into two groups: short-term (<4 weeks) sodium-glucose cotransporter 2 inhibitor (SGLT2i) group (213 patients) and control group (213 patients). The occurrence of contrast-induced acute kidney injury (CIAKI) after PCI was compared between the two groups. The results showed that the incidence of CIAKI in the SGLT2i group was not significantly different from the control group [10.8% (23/213) vs. 7.5% (16/213), χ2=1.383, P=0.313]. The incidence of CIAKI in patients with SGLT2i application time <1 week was higher than that in control patients, but the difference was not statistically significant [13.00% (16/123) vs. 7.5% (16/213), χ2=2.734, P=0.122]. Multivariate logistic regression analysis showed that short-term (<4 weeks) use of SGLT2i would not increase the risk of CIAKI after PCI in T2DM patients ( OR=0.507, 95% CI 0.238-1.077, P=0.077). Short-term application of SGLT2i before PCI may not increase the risk of CIAKI, but it is advisable to avoid initiating the application of SGLT2i before PCI as much as possible.
